Literature DB >> 11715248

[The Malmo model for private and public rheumatological outpatient care. Cooperation makes it possible to introduce disease modifying treatment quickly].

L Jacobsson1, Y Lindroth, L Marsal, L Tejler.   

Abstract

The Malmö model represents a close collaboration between private practitioners who receive public financing and hospital-based rheumatological clinics. A comparison of these two types of out-patient care was undertaken by questionnaire in 1997 (70% response rate). Of the total patient cohort in the study, 73% were seen by private rheumatologists. The evaluation showed very similar outcomes, regardless of drug treatment employed or professional personnel involved (i.e., a physician or other members of the rheumatological team). Minor differences concerned easier accessibility to physicians in private practice, and the large proportion of immigrants seen at the hospital clinic. The results of the study confirmed the similarity of care provided in both types of out-patient clinics. Improved pharmacological products for suppressing inflammation will lead to increasing demands on out-patient rheumatological care. The model described illustrates a method of meeting those demands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11715248

Source DB:  PubMed          Journal:  Lakartidningen        ISSN: 0023-7205


  7 in total

1.  Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis--results from a well defined population in south Sweden.

Authors:  Korosh Hekmat; Lennart Jacobsson; Jan-Åke Nilsson; Ingemar F Petersson; Otto Robertsson; Göran Garellick; Carl Turesson
Journal:  Arthritis Res Ther       Date:  2011-04-21       Impact factor: 5.156

2.  Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.

Authors:  C Turesson; L T H Jacobsson; G Sturfelt; E L Matteson; L Mathsson; J Rönnelid
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

3.  Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek
Journal:  Ann Rheum Dis       Date:  2006-12-11       Impact factor: 19.103

4.  Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Authors:  G Kobelt; P Lindgren; A Singh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

5.  The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis.

Authors:  Carl Turesson; Daniel J Schaid; Cornelia M Weyand; Lennart T H Jacobsson; Jörg J Goronzy; Ingemar F Petersson; Gunnar Sturfelt; Britt-Marie Nyhäll-Wåhlin; Lennart Truedsson; Sonja A Dechant; Eric L Matteson
Journal:  Arthritis Res Ther       Date:  2005-10-11       Impact factor: 5.156

6.  Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.

Authors:  Britta Strömbeck; Lennart T H Jacobsson; Ann Bremander; Martin Englund; Anders Heide; Aleksandra Turkiewicz; Ingemar F Petersson
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

7.  Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study.

Authors:  Korosh Hekmat; Lennart T Jacobsson; Jan-Åke Nilsson; Ylva Lindroth; Carl Turesson
Journal:  BMC Musculoskelet Disord       Date:  2014-02-20       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.